Specific inhibition effects of N -pentafluorobenzyl-1-deoxynojirimycin on human CD4+ T cells

Bioorganic & Medicinal Chemistry Letters
2004.0

Abstract

We first synthesized N-pentafluorobenzyl-1-deoxynojirimycin (5F-DNM), one new derivative of 1-deoxynojirimycin (DNM). Effects on human peripheral blood mononuclear cells (PMBC) and secretion of cytokines from human PBMC by 5F-DNM were investigated. It was first found that 5F-DNM remarkably inhibited the secretion of interleukin-4 (IL-4) and had a specific inhibition on the expression of CD4 molecules. 5F-DNM, much less toxic than cyclosporin A, might be used as a new candidate of immunosuppressant for specifically treating Th2-mediated immune diseases.

Knowledge Graph

Similar Paper

Specific inhibition effects of N -pentafluorobenzyl-1-deoxynojirimycin on human CD4+ T cells
Bioorganic & Medicinal Chemistry Letters 2004.0
An iminosugar N-pentafluorobenzyl-1-deoxynojirimycin as a novel potential immunosuppressant for the treatment of Th2-related diseases
Bioorganic & Medicinal Chemistry Letters 2012.0
An expeditious one-pot synthesis of 1,6-dideoxy-N-alkylated nojirimycin derivatives and their inhibitory effects on the secretion of IFN-γ and IL-4
Bioorganic & Medicinal Chemistry 2008.0
Synthetic Iminosugar Derivatives as New Potential Immunosuppressive Agents
Journal of Medicinal Chemistry 2005.0
Dethymicin, a novel immunosuppressant isolated from an Amycolatopsis. Fermentation, isolation, physico-chemical properties and biological activities.
The Journal of Antibiotics 1992.0
Discovery of 7-N-Piperazinylthiazolo[5,4-d]pyrimidine Analogues as a Novel Class of Immunosuppressive Agents with in Vivo Biological Activity
Journal of Medicinal Chemistry 2011.0
N-(8-(3-Ethynylphenoxy)octyl-1-deoxynojirimycin suppresses growth and migration of human lung cancer cells
Bioorganic & Medicinal Chemistry Letters 2010.0
Synthesis, biological evaluation of chrysin derivatives as potential immunosuppressive agents
European Journal of Medicinal Chemistry 2011.0
RETRACTED: Deoxynojirimycin and its hexosaminyl derivatives bind to natural killer cell receptors rNKR-P1A and hCD69
Bioorganic & Medicinal Chemistry Letters 2010.0
In Vivo Activities.
The Journal of Antibiotics 2003.0